Tango Therapeutics (TNGX) news
Recent news
Tango Therapeutics, Inc.: H.C. Wainwright raises target price to $68 from $66
H.C. Wainwright has raised its price target for Tango Therapeutics, Inc. (NASDAQ:TNGX) to $68 from $66, while maintaining a Buy rating . This adjustment follows the release of promising Phase 1 trial data for the combination therapy of vopimetostat and daraxonrasib in patients with pancreatic…
AInvest Wire · Aug 18, 2026Perceptive Advisors boosts Syre, Rlay, Tngx, Rytm in 2Q: 13F
AInvest Wire · Aug 14, 2026Tango Therapeutics - files prospectus to sell up to $400 mln in common stock - SEC filing
AInvest Wire · Aug 11, 2026Tango Therapeutics announces executive chair transition
Tango Therapeutics, Inc. (NASDAQ: TNGX) has announced a leadership transition within its executive and board structure. Dr. Barbara Weber, the company’s founding Chief Executive Officer, has retired from her role as CEO and will assume the position of Executive Chair of the board of directors,…
AInvest Wire · Aug 6, 2026Tango Therapeutics - Barbara Weber's employment as executive chair ended on August 3, 2026 - SEC filing
Tango Therapeutics, Inc. (NASDAQ: TNGX) has announced that Barbara Weber, M.D., former Executive Chair of the board of directors, officially ended her role on August 3, 2026, as disclosed in a recent SEC filing. Dr. Weber had transitioned from her role as CEO to Executive Chair in January 2026,…
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.